Lisi M Dredze1,2, Michael Friger1,3, Samuel Ariad1,2, Michael Koretz1,4, Bertha Delgado1,5, Ruthy Shaco-Levy1,5, Margarita Tokar1,2, Michael Bayme1,4, Ravit Agassi1,4, Maia Rosenthal1,6, Victor Dyomin1,5, Olga Belochitski1,2, Shai Libson1,4, Tamar Mizrahi1,2, David B Geffen7,8. 1. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. 2. Department of Oncology, Soroka University Medical Center, Beer Sheva, Israel. 3. Department of Public Health, Ben-Gurion University of the Negev, Beer Sheva, Israel. 4. Division of Surgery and The Eshkol Breast Center, Soroka Medical Center, Beer Sheva, Israel. 5. Department of Pathology, Soroka University Medical Center, Beer Sheva, Israel. 6. Department of Imaging and The Eshkol Breast Center, Soroka Medical Center, Beer Sheva, Israel. 7. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. dgeffen@bgu.ac.il. 8. Department of Oncology, Soroka University Medical Center, Beer Sheva, Israel. dgeffen@bgu.ac.il.
Abstract
PURPOSE: We analyzed outcomes of doxorubicin-cyclophosphamide (AC) followed by weekly paclitaxel as neoadjuvant chemotherapy (NAC) for breast cancer (BC), in an everyday practice with long-term follow-up of patients. METHODS: All patients (n = 200) who received the AC-paclitaxel combination as NAC for BC at the Soroka University Medical Center from 2003 to 2012 were included in this retrospective cohort study. AC was administered on an every 3-week schedule (standard dose) until May, 2007 (n = 99); and subsequently every 2-week dose dense (dd) (n = 101). Clinical pathologic features, treatment course, and outcome information were recorded. Complete pathologic response (pCR) was analyzed according to BC subtype, dose regimen, and stage. RESULTS: Median age was 49 years; 55.5% and 44.5% of patients were clinically stage 2 and 3, respectively. Standard dose patients had more T3 tumors. Subtypes were human epidermal growth factor receptor-2 (HER2)-positive 32.5% (of whom 82% received trastuzumab), hormone receptor-positive/HER2-negative 53%, and triple negative 14.5%. Breast-conserving surgery (BCS) was performed in 48.5% of patients; only 9.5% were deemed suitable for BCS prior to NAC. Toxicity was acceptable. The overall pCR rate was 26.0% and was significantly higher in the dd group and HER2-positive patients. With a median follow-up of 9.51 years median event-free survival (EFS) and overall survival (OS) are 10.85 years and 12.61 years, respectively. Patients achieving pCR had significantly longer EFS and OS. CONCLUSION: NAC for BC with AC-paclitaxel can be safely administered in the "real-world' setting with high efficacy. Current efforts are aimed at increasing rates of pCR and identifying patients who may benefit from additional therapy or conversely, de-escalated treatment.
PURPOSE: We analyzed outcomes of doxorubicin-cyclophosphamide (AC) followed by weekly paclitaxel as neoadjuvant chemotherapy (NAC) for breast cancer (BC), in an everyday practice with long-term follow-up of patients. METHODS: All patients (n = 200) who received the AC-paclitaxel combination as NAC for BC at the Soroka University Medical Center from 2003 to 2012 were included in this retrospective cohort study. AC was administered on an every 3-week schedule (standard dose) until May, 2007 (n = 99); and subsequently every 2-week dose dense (dd) (n = 101). Clinical pathologic features, treatment course, and outcome information were recorded. Complete pathologic response (pCR) was analyzed according to BC subtype, dose regimen, and stage. RESULTS: Median age was 49 years; 55.5% and 44.5% of patients were clinically stage 2 and 3, respectively. Standard dose patients had more T3 tumors. Subtypes were human epidermal growth factor receptor-2 (HER2)-positive 32.5% (of whom 82% received trastuzumab), hormone receptor-positive/HER2-negative 53%, and triple negative 14.5%. Breast-conserving surgery (BCS) was performed in 48.5% of patients; only 9.5% were deemed suitable for BCS prior to NAC. Toxicity was acceptable. The overall pCR rate was 26.0% and was significantly higher in the dd group and HER2-positive patients. With a median follow-up of 9.51 years median event-free survival (EFS) and overall survival (OS) are 10.85 years and 12.61 years, respectively. Patients achieving pCR had significantly longer EFS and OS. CONCLUSION: NAC for BC with AC-paclitaxel can be safely administered in the "real-world' setting with high efficacy. Current efforts are aimed at increasing rates of pCR and identifying patients who may benefit from additional therapy or conversely, de-escalated treatment.
Authors: C Mazouni; S-W Kau; D Frye; F Andre; H M Kuerer; T A Buchholz; W F Symmans; K Anderson; K R Hess; A M Gonzalez-Angulo; G N Hortobagyi; A U Buzdar; L Pusztai Journal: Ann Oncol Date: 2007-02-10 Impact factor: 32.976
Authors: B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Nathalie LeVasseur; J Sun; L Gondara; R Diocee; C Speers; C Lohrisch; S Chia Journal: J Cancer Res Clin Oncol Date: 2019-11-18 Impact factor: 4.553
Authors: Michael Untch; Volker Möbus; Walther Kuhn; Bernd Rudolph Muck; Christoph Thomssen; Ingo Bauerfeind; Nadia Harbeck; Christoph Werner; Annette Lebeau; Andreas Schneeweiss; Stephen Kahlert; Franz von Koch; Karl Ulrich Petry; Diethelm Wallwiener; Rolf Kreienberg; Ute-Susann Albert; Hans-Joachim Lück; Axel Hinke; Fritz Jänicke; Gottfried E Konecny Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Julie R Gralow; Harold J Burstein; William Wood; Gabriel N Hortobagyi; Luca Gianni; Gunter von Minckwitz; Aman U Buzdar; Ian E Smith; William F Symmans; Baljit Singh; Eric P Winer Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544